A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DAD / Disability Assessment for Dementia

[Related PubMed/MEDLINE]
Total Number of Papers: 101
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DAD  (>> Co-occurring Abbreviation)
Long Form:   Disability Assessment for Dementia
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Pronounced Impairment of Activities of Daily Living in Posterior Cortical Atrophy. AD, ADLs, PCA
2019 Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial. CDR, GDS, MCI, MMSE, NTB
2019 Promoting activity, Independence and stability in early dementia (PrAISED): a, multisite, randomised controlled, feasibility trial. PrAISED
2019 Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer's Disease. AD, DLB, GDS, QOL
2018 Apathy and functional disability in behavioral variant frontotemporal dementia. ACE-R, BADL, bvFTD, CDR, IADL, NPI
2018 Improving Cognition through Dance in Older Filipinos with Mild Cognitive Impairment. ADAS-Cog, BNT, GDS, IADL, MCI
2018 Is it feasible to deliver a complex intervention to improve the outcome of falls in people with dementia? A protocol for the DIFRID feasibility study. GAS, HUQ, MFES, MoCA, PwD, QOL-AD, ZBI
2018 Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study. AD, ADAS-Cog, ARIA-E, OLE, s.c, TEAEs
2017 Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials. AD, ADAS, CI, MD, MMSE, RR
10  2017 Benefits of Occupational Therapy in Dementia Patients: Findings from a Real-World Observational Study. MMSE, NPI, OT
11  2017 Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. AD
12  2017 Measurement of Functional Cognition and Complex Everyday Activities in Older Adults with Mild Cognitive Impairment and Mild Dementia: Validity of the Large Allen's Cognitive Level Screen. AMPS, CN, LACLS-5, MCI
13  2017 Modeling Alzheimer Disease Through Functional Independence and Participation. AD
14  2017 Physical Exercise Helped to Maintain and Restore Functioning in Chinese Older Adults With Mild Cognitive Impairment: A 5-Year Prospective Study of the Hong Kong Memory and Ageing Prospective Study (HK-MAPS). CMMSE, HK-MAPS
15  2017 Translation and adaptation of the Disability Assessment for Dementia scale in the Spanish population. CI
16  2016 Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study. MMSE
17  2016 Factors associated with caregiver burden: comparative study between Brazilian and Spanish caregivers of patients with Alzheimer's disease (AD). AD, CDR, FAQ, MMSE, NPI, ZBI
18  2016 Predictors of functional disability in mild cognitive impairment and dementia. CDR, MCI
19  2015 Alzheimer's disease progression model using disability assessment fordementia scores from bapineuzumab trials. AD, YSO
20  2015 Direct and indirect assessments of activities of daily living in behavioral variant frontotemporal dementia and Alzheimer disease. AD, ADLs, bvFTD, NCs
21  2015 Longitudinal costs of caring for people with Alzheimer's disease. DS, ECAD, SD
22  2015 Neuropsychiatric Symptoms, Caregiver Burden and Distress in Behavioral-Variant Frontotemporal Dementia and Alzheimer's Disease. AD, bvFTD, CSDD, GAI, NPI
23  2015 The reliability and validity of the Turkish version of the Neuropsychiatric Inventory-Clinician. AD, BEHAVE-AD, IADL, MMSE, NPI-C
24  2014 Functional disability in Alzheimer disease: a validation study of the Turkish version of the disability assessment for dementia scale. AD, ADL, GDS, IADL, ICC, MMSE
25  2014 Influence of vascular risk factors and neuropsychological profile on functional performances in CADASIL: results from the MIcrovascular LEukoencephalopathy Study (MILES). ARL, CADASIL, MILES
26  2014 Measuring life space in older adults with mild-to-moderate Alzheimer's disease using mobile phone GPS. AD, CTL, GPS
27  2014 Modeling of bounded outcome scores with data on the boundaries: application to disability assessment for dementia scores in Alzheimer's disease. BR, CO, VPC
28  2014 NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. AD, CDR-SB
29  2014 Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease. AD, ADAS-Cog, NTB
30  2013 Assessment of instrumental activities of daily living in dementia: diagnostic value of the Amsterdam Instrumental Activities of Daily Living Questionnaire. AUCs, CI, IADL, MMSE
31  2013 Cognitive change in donepezil treated patients with vascular or mixed dementia. CGI, CI, SG, sMMSE, SRMs, VaD
32  2013 Factors associated with the variability in caregiver assessments of the capacities of patients with Alzheimer disease. AD, AQ-D, CC, NPI, QoL-AD
33  2013 Functional profile of patients with behavioral variant frontotemporal dementia (bvFTD) compared to patients with Alzheimer's disease and normal controls. AD, bvFTD, CDR, GDS, MMSE
34  2013 Longitudinal changes in functional disability in Alzheimer's disease patients. AD, ADL, MMSE
35  2013 Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study. AD, ADAS-cog, CGIC, NPI, ROSA, SIB
36  2012 Activities of daily living in progressive non-fluent aphasia, logopenic progressive aphasia and Alzheimer's disease. ACE-R, AD, ADLs, CBI-R, LPA, PNFA
37  2012 DAD-6: A 6-ltem version of the Disability Assessment for Dementia scale which may differentiate Alzheimer's disease and mild cognitive impairment from controls. MCI, MD
38  2012 Effects of yokukansan on behavioral and psychological symptoms of vascular dementia: an open-label trial. BI, BPSD, MMSE, NPI, UPDRS, VaD
39  2012 Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine. BPSD, YKS
40  2012 Reassessment of the dementia diagnosis of Alzheimer's disease in patients enrolled on the cholinesterase inhibitors dispensation program. AD, AD, MMSE
41  2012 The Danish version of the Baylor Profound Mental State Examination. GDS, MMSE, SIB
42  2011 A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. AD
43  2011 Assessment of balance in mild and moderate stages of Alzheimer's disease: implications on falls and functional capacity. AD, BBS
44  2011 Do patients diagnosed with Alzheimer's disease benefit from a psycho-educational programme for family caregivers? A randomised controlled study. AD, AIDMA, MADRS, NPI, PEP, SCQ, VAS
45  2011 Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study. AD, ADAS-Cog, ADCS-CGIC, MMSE, NNRs
46  2011 Memantine in behavioral variant frontotemporal dementia: negative results. bvFTD, DBPC, FBI, MDRS, MMSE, NPI, ZBI
47  2011 Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients. NPI
48  2011 [Disability Assessment for Dementia (DAD), Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)]. ADCS-ADL
49  2010 Assessment of potential measures in models of progression in Alzheimer disease. AD, CDR, DS, DS, MMSE, QOL
50  2010 Differentiating the frontal variant of Alzheimer's disease. AD, FBI, FRS, FTD, NPI
51  2010 Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease. AD, BPSD, MMSE, NPI, SDS, YKS
52  2010 Five Alzheimer's disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin. BPSD, DIEEPS, MMSE, NPI, RAGE
53  2010 Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. AD, ADAS-cog, CDR, MRS, NAA, NPI, PCG
54  2010 Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice. AD, ADL, BPSD, MMSE, NPI, SDS
55  2009 Brazilian caregiver version of the Apathy Scale. AD, AS, NPI
56  2009 Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial. ADAS-cog, IMT, NPI
57  2009 Emotion, social functioning and activities of daily living in frontotemporal dementia. ADL, bv-FTD, CBI
58  2009 Long-term treatment of patients with Alzheimer's disease in primary and secondary care: results from an international survey. AChEIs, AD, AEs, CGI, IOSID, MMSE, NPI
59  2009 Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. AChEIs, AD, CVD, MMSE, NHP, SE
60  2009 [A longitudinal study of apathy in patients with Alzheimer's disease]. AD, CAMCOG-R, NPI
61  2008 Behavioral and activities of daily living inventories in the diagnosis of frontotemporal lobar degeneration and Alzheimer's disease. AD, FBI, FTLD
62  2008 Correlates of intrusion and avoidance as stress response symptoms in family carers of patients suffering from dementia. GDS, IES, MMSE, NPI, STAI
63  2008 Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. ADAS-Cog, ChEIs
64  2008 The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort. AD, ADLs, ChEIs
65  2008 Transition from cognitively impaired not demented to Alzheimer's disease: an analysis of changes in functional abilities in a dementia clinic cohort. AD, CIND, FRS, IADL
66  2008 Zarit burden inventory and activities of daily living in the behavioral variant of frontotemporal dementia. AD, ADL, FTD, MDRS, NPI, ZBI
67  2008 [Memantine (akatinol) therapy of cognitive impairment in Parkinson's disease complicated by dementia]. FAB, MMSE, PDD, UPDRS
68  2007 Activities of daily living in frontotemporal dementia and Alzheimer disease. ACE-R, ADLs, BADLs, IADL, CDR
69  2007 Characteristic profiles of instrumental activities of daily living in Chinese older persons with mild cognitive impairment. AD, aMCI, IADL, MCI, md-MCI, NC
70  2007 Depression and apathy affect functioning in community active subjects with questionable dementia and mild Alzheimer's disease. AD, QD
71  2007 Patients with Lewy body dementia use more resources than those with Alzheimer's disease. AD, DLB, MMSE, NPI, RUD Lite
72  2007 Reliability study on the Japanese version of the Clinician's Interview-Based Impression of Change. Analysis of subscale items and 'clinician's impression'. BEHAVE-AD, CGIC, MENFIS
73  2007 The relative stress scale, a useful instrument to identify various aspects of carer burden in dementia? MMSE, NPI, RSS
74  2007 [Cross-cultural adaptation of the Disability Assessment for Dementia (DAD)]. ---
75  2006 Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CBS, CIBIC-plus, GAS, SD, SRMs
76  2006 Cholinesterase inhibitors slow decline in executive functions, rather than memory, in Alzheimer's disease: a 1-year observational study in the Sunnybrook dementia cohort. DRS, MMSE
77  2006 Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease. APOE, BEHAVE-AD, CIBIC-plus
78  2006 Galantamine for Alzheimer's disease and mild cognitive impairment. AD, ADAS-cog, ADCS-ADL, MCI, NPI
79  2006 Leukoaraiosis predicts hidden global functioning impairment in nondisabled older people: the LADIS (Leukoaraiosis and Disability in the Elderly) Study. ---
80  2006 Validation of the Chinese Challenging Behaviour Scale: clinical correlates of challenging behaviours in nursing home residents with dementia. BPSD, CCBS, CDR, MMSE, NPI
81  2005 Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. AD, ADAS-cog, ADL, MMSE
82  2004 A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. AD, FAST, MMSE
83  2004 Effects of galantamine in patients with mild Alzheimer's disease. AD, ADAS-cog, CIBIC, MMSE, PLAC
84  2004 Galantamine for Alzheimer's disease. AD, ADAS-cog, ADCS-ADL, NPI
85  2004 Visuospatial inattention and daily life performance in people with Alzheimer's disease. BIT, FSAQ, MMSE
86  2003 An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. AD, CVD, NPI, SE, SE, VaD
87  2003 Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. AD, ADLs, CSS, IADL, LOCF
88  2002 Galantamine for Alzheimer's disease. AD, ADAS-cog, NPI, OR
89  2002 The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patients. AChE, AD, ADCS/ADL, ADL, ChE, PDS
90  2002 The effect of the living situation on the severity of dementia at diagnosis. CIRS, FRS, GDS, MMSE
91  2002 To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers? MMSE
92  2001 APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. AD, APOE
93  2001 Galantamine for Alzheimer's disease. ADAS-cog, ADCS-ADL, BIOMED, NPI, NRR, OR
94  2001 Galantamine for Alzheimer's disease. AD, ADAS-cog, ADCS-ADL, ADEAR, NPI, OR
95  2001 Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease. ADL, CVD, VaD
96  2001 The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease. AD, ADLs
97  2000 Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. CIBIC-plus
98  2000 Galantamine: therapeutic effects beyond cognition. AD, ADL, NPI, PSQI
99  1999 Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. ---
100  1999 The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. ADAS-Cog, CIBIC-Plus, MMSE, NPI